Given the challenges of assessing prostate cancer risk, we believe Apifiny has the potential to make a real difference in improving the detection of prostate cancer.
KALAMAZOO, MI (PRWEB) January 21, 2016
Armune BioScience signed a definitive agreement with Vantari International to offer Apifiny® to their rapidly growing international laboratory services in Dubai and Brazil. Launched in the United States in April of 2015, Apifiny is the only cancer specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to help move beyond PSA based testing to assess prostate cancer risk.
Armune BioScience, Inc. is a Michigan-based life sciences company that developed Apifiny. Apifiny was developed based on innovative research into the immune system’s response to cancer conducted at the University of Michigan. Armune is currently expanding testing throughout the United States and preparing to expand into several markets worldwide in the coming months.
“Armune is excited to be partnering with Vantari International to expand access to Apifiny,” commented David Esposito, President and CEO of Armune BioScience. “Vantari has a rapidly growing international presence and we look forward to Apifiny supporting their growth in the large markets of Dubai and Brazil.”
In many markets around the world, patients with an elevated PSA and other risks factors for prostate cancer (abnormal digital rectal exam, family history, race, etc.) will undergo a prostate biopsy. The current process to determine candidates for an initial or repeat biopsy results in too many biopsies being performed. Apifiny has the potential to aid clinicians in determining the most appropriate candidates for an initial or repeat biopsy and to better address the global healthcare system’s demand for improved outcomes at lower costs.
“Vantari International continues to be a leader in bringing innovative diagnostic tools to our clients in the US and several global markets. We look forward to offering Apifiny to our clients in Brazil and Dubai,” said Nick Arroyo CEO of Vantari International. “Given the challenges of assessing prostate cancer risk, we believe Apifiny has the potential to make a real difference in improving the detection of prostate cancer.”
About Vantari Genetics International (http://www.vantarigenetics.com)
At Vantari Genetics, we challenge the idea that people have limited control over their health futures. With a focus on genetics, we believe we can abandon the cure driven approach and move to a proactive approach — from anticipating drug interactions to analyzing risks for inherited diseases and cancer. At our roots, we are a clinical laboratory specializing in genetics. Just like you, illness, disease and cancer hit close to home for us. We knew there had to be a solution and we were determined to find it – and share it.
About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.